Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease

Cell Death and Disease

Volumn 5, Issue 9, 2014, Pages

  Scuderi, C ^a   Stecca, C ^a   Valenza, M ^b   Ratano, P ^a   Bronzuoli, M R ^a   Bartoli, S ^a   Steardo, L ^a,c   Pompili, E ^a   Fumagalli, L ^a   Campolongo, P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ROCKEFELLER UNIVERSITY   (United States)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ANTIINFLAMMATORY AGENT; GW 6471; NEUROPROTECTIVE AGENT; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PROTEIN S100B; TAU PROTEIN; UNCLASSIFIED DRUG; ETHANOLAMINE DERIVATIVE; PALMITIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ADULT; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN FUNCTION; BRAIN INJURY; COGNITIVE DEFECT; DISEASE COURSE; DRUG MECHANISM; GLIOSIS; HIPPOCAMPAL CA3 REGION; IMMUNOFLUORESCENCE; INTRAHIPPOCAMPAL DRUG ADMINISTRATION; INVESTIGATIVE PROCEDURES; LEARNING; LONG TERM MEMORY; MALE; MORRIS WATER MAZE TEST; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WNT SIGNALING PATHWAY; ANIMAL; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; ETHANOLAMINES; GLIOSIS; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PALMITIC ACIDS; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84927733866     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.376     Document Type: Article

References (69)

1. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362: 329-344.
2. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010; 9: 1118-1127.
3. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006; 368: 387-403.
4. Mrak RE, Griffin WS. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging 2001; 22: 903-908.
5. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006; 12: 1005-1015.
6. Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005; 76: 77-98.
7. Verkhratsky A, Rodriguez JJ, Steardo L. Astrogliopathology: a central element of neuropsychiatric diseases? Neuroscientist 3 December 2013; e-pub ahead of print.
8. Fuller S, Steele M, Munch G. Activated astroglia during chronic inflammation in Alzheimer's disease-do they neglect their neurosupportive roles? Mutat Res 2009; 690: 40-49.
9. Medeiros R, LaFerla FM. Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol 2013; 239: 133-138.
10. Esposito G, Scuderi C, Valenza M, Togna GI, Latina V, De Filippis D et al. Cannabidiol reduces Abeta-induced neuroinflammation and promotes hippocampal neurogenesis through PPARgamma involvement. PLoS One 2011; 6: e28668.
11. Cowley TR, O'Sullivan J, Blau C, Deighan BF, Jones R, Kerskens C et al. Rosiglitazone attenuates the age-related changes in astrocytosis and the deficit in LTP. Neurobiol Aging 2012; 33: 162-175.
12. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005; 67: 15-19.
13. Mackie K, Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 2006; 8: E298-E306.
14. Cadas H, di Tomaso E, Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci 1997; 17: 1226-1242.
15. Murillo-Rodriguez E, Desarnaud F, Prospero-Garcia O. Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. Life Sci 2006; 79: 30-37.
16. Skaper SD, Facci L, Romanello S, Leon A. Mast cell activation causes delayed neurodegeneration in mixed hippocampal cultures via the nitric oxide pathway. J Neurochem 1996; 66: 1157-1166.
17. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394: 277-281.
18. Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci 2003; 23: 7767-7775.
19. Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med 2012; 13: 1121-1130.
20. Keppel Hesselink JM, de Boer T, Witkamp RF. Palmitoylethanolamide: a natural body-own anti-inflammatory agent, effective and safe against influenza and common cold. Int J Inflam 2013; 2013: 151028.
21. LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G et al. Rapid broadspectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 2006; 319: 1051-1061.
22. Scuderi C, Valenza M, Stecca C, Esposito G, Carratu MR, Steardo L. Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-alpha. J Neuroinflammation 2012; 9: 49.
23. Scuderi C, Steardo L. Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer's disease. CNS Neurol Disord Drug Targets 2013; 12: 62-69.
24. Petrosino S, Iuvone T, Di Marzo V. N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. Biochimie 2010; 92: 724-727.
25. Scuderi C, Esposito G, Blasio A, Valenza M, Arietti P, Steardo L Jr. et al. Palmitoylethanolamide counteracts reactive astrogliosis induced by beta-amyloid peptide. J Cell Mol Med 2011; 15: 2664-2674.
26. Verkhratsky A, Parpura V. Recent advances in (patho)physiology of astroglia. Acta Pharmacol Sin 2010; 31: 1044-1054.
27. Verkhratsky A, Sofroniew MV, Messing A, deLanerolle NC, Rempe D, Rodriguez JJ et al. Neurological diseases as primary gliopathies: a reassessment of neurocentrism. ASN Neuro 2012; 4: e00082.
28. Verkhratsky A, Butt AM. Glial Neurobiology United KingdomJohn Wiley and Sons Ltd, 2007.
29. Donato R, Heizmann CW. S100B protein in the nervous system and cardiovascular apparatus in normal and pathological conditions. Cardiovasc Psychiatry Neurol 2010; 2010: 929712.
30. Steiner J, Bogerts B, Schroeter ML, Bernstein HG. S100B protein in neurodegenerative disorders. Clin Chem Lab Med 2011; 49: 409-424.
31. Sastre M, Klockgether T, Heneka MT. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci 2006; 24: 167-176.
32. Griffin WS. Alzheimer's-Looking beyond plaques. F1000 Med Rep 2011; 3: 24.
33. Ben Menachem-Zidon O, Menahem YB, Hur TB, Yirmiya R. Intra-hippocampal transplantation of neural precursor cells with transgenic over-expression of IL-1 receptor antagonist rescues memory and neurogenesis impairments in an alzheimer's disease model. Neuropsychopharmacology 2013; 39: 401-414.
34. Mrak RE. Neuropathology and the neuroinflammation idea. J Alzheimers Dis 2009; 18: 473-481.
35. Rojo LE, Fernandez JA, Maccioni AA, Jimenez JM, Maccioni RB. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 2008; 39: 1-16.
36. Frankola KA, Greig NH, Luo W, Tweedie D. Targeting TNF-alpha to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol Disord Drug Targets 2011; 10: 391-403.
37. Hallenbeck J. How inflammation modulates central nervous system vessel activation and provides targets for intervention-a personal perspective. Ann N Y Acad Sci 2010; 1207: 1-7.
38. Koistinaho J, Malm T, Goldsteins G. Glycogen synthase kinase-3beta: a mediator of inflammation in Alzheimer's disease? Int J Alzheimers Dis 2011; 2011: 129753.
39. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 2009; 4: 47.
40. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004; 63: 901-910.
41. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 2001; 4: 231-232.
42. Cole SL, Vassar R. BACE1 structure and function in health and Alzheimer's disease. Curr Alzheimer Res 2008; 5: 100-120.
43. Li Y, Zhou W, Tong Y, He G, Song W. Control of APP processing and Abeta generation level by BACE1 enzymatic activity and transcription. FASEB J 2006; 20: 285-292.
44. Rodrigues EM, Weissmiller AM, Goldstein LS. Enhanced beta-secretase processing alters APP axonal transport and leads to axonal defects. Hum Mol Genet 2012; 21: 4587-4601.
45. Theuns J, Van Broeckhoven C. Transcriptional regulation of Alzheimer's disease genes: implications for susceptibility. Hum Mol Genet 2000; 9: 2383-2394.
46. Gentleman SM, Nash MJ, Sweeting CJ, Graham DI, Roberts GW. Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury. Neurosci Lett 1993; 160: 139-144.
47. Caricasole A, Copani A, Caruso A, Caraci F, Iacovelli L, Sortino MA et al. The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer's disease? Trends Pharmacol Sci 2003; 24: 233-238.
48. Inestrosa NC, Montecinos-Oliva C, Fuenzalida M. Wnt signaling: role in Alzheimer disease and schizophrenia. J Neuroimmune Pharmacol 2012; 7: 788-807.
49. Esposito G, Scuderi C, Lu J, Savani C, De Filippis D, Iuvone T et al. S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. J Cell Mol Med 2008; 12: 914-927.
50. Zenzmaier C, Marksteiner J, Kiefer A, Berger P, Humpel C. Dkk-3 is elevated in CSF and plasma of Alzheimer's disease patients. J Neurochem 2009; 110: 653-661.
51. Cavallini A, Brewerton S, Bell A, Sargent S, Glover S, Hardy C et al. An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease. J Biol Chem 2013; 288: 23331-23347.
52. Hirokawa N. Microtubule organization and dynamics dependent on microtubule-associated proteins. Curr Opin Cell Biol 1994; 6: 74-81.
53. Dehghani L, Hashemi-Beni B, Poorazizi E, Khorvash F, Shaygannejad V, Sedghi M et al. Evaluation of neural gene expression in serum treated embryonic stem cells in Alzheimer's patients. J Res Med Sci 2013; 18(Suppl 1): S20-S23.
54. O'Callaghan JP, Sriram K. Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. Expert Opin Drug Saf 2005; 4: 433-442.
55. Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ et al. Functions of S100 proteins. Curr Mol Med 2013; 13: 24-57.
56. Blasko I, Veerhuis R, Stampfer-Kountchev M, Saurwein-Teissl M, Eikelenboom P, Grubeck-Loebenstein B. Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1-40 and Abeta1-42 by human astrocytes. Neurobiol Dis 2000; 7(6 Pt B): 682-689.
57. Luterman JD, Haroutunian V, Yemul S, Ho L, Purohit D, Aisen PS et al. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol 2000; 57: 1153-1160.
58. Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller AJ, Caruso A et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci 2004; 24: 6021-6027.
59. Morris RG. Episodic-like memory in animals: psychological criteria, neural mechanisms and the value of episodic-like tasks to investigate animal models of neurodegenerative disease. Philos Trans R Soc Lond B Biol Sci 2001; 356: 1453-1465.
60. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP et al. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 2005; 18: 602-617.
61. Sexton CE, Mackay CE, Lonie JA, Bastin ME, Terriere E, O'Carroll RE et al. MRI correlates of episodic memory in Alzheimer's disease, mild cognitive impairment, and healthy aging. Psychiatry Res 2010; 184: 57-62.
62. Espinosa A, Alegret M, Valero S, Vinyes-Junque G, Hernandez I, Mauleon A et al. A longitudinal follow-up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved. J Alzheimers Dis 2012; 34: 769-780.
63. Paxinos G, Watson C. The Rat Brain In Stereotaxic Coordinates, 2007.
64. Duran-Gonzalez J, Michi ED, Elorza B, Perez-Cordova MG, Pacheco-Otalora LF, Touhami A et al. Amyloid beta peptides modify the expression of antioxidant repair enzymes and a potassium channel in the septohippocampal system. Neurobiol Aging 2013; 34: 2071-2076.
65. De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging 2008; 29: 1334-1347.
66. Sheerin AH, Zhang X, Saucier DM, Corcoran ME. Selective antiepileptic effects of N-palmitoylethanolamide, a putative endocannabinoid. Epilepsia 2004; 45: 1184-1188.
67. Kapoor A, Collino M, Castiglia S, Fantozzi R, Thiemermann C. Activation of peroxisome proliferator-activated receptor-beta/delta attenuates myocardial ischemia/reperfusion injury in the rat. Shock 2010; 34: 117-124.
68. Koistinaho M, Ort M, Cimadevilla JM, Vondrous R, Cordell B, Koistinaho J et al. Specific spatial learning deficits become severe with age in beta-amyloid precursor protein transgenic mice that harbor diffuse beta-amyloid deposits but do not form plaques. Proc Natl Acad Sci USA 2001; 98: 14675-14680.
69. Campolongo P, Ratano P, Ciotti MT, Florenzano F, Nori SL, Marolda R et al. Systemic administration of substance p recovers Beta amyloid-induced cognitive deficits in rat: involvement of kv potassium channels. PLoS One 2013; 8: e78036.